This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Men's Health  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Results From the Boston Area Community Health Survey

Susan A. Hall, PhD; Andre B. Araujo, PhD; Gretchen R. Esche, MS; Rachel E. Williams, PhD; Richard V. Clark, MD, PhD; Thomas G. Travison, PhD; John B. McKinlay, PhD

Arch Intern Med. 2008;168(10):1070-1076.

Background  Despite the aging of the US population and increasing sales of prescription testosterone, treatment patterns for androgen deficiency (AD) are poorly understood. We describe patterns and correlates of testosterone treatment in community-dwelling men.

Methods  The Boston Area Community Health Survey is an observational study of a population-based random sample of racially and ethnically diverse men representative of Boston, Massachusetts. Data collected by in-person interview from April 2002 to June 2005 included health status, socioeconomic status, access to medical care, and use of prescription medications. A venous blood sample was collected. The operational definition of untreated AD was serum total testosterone level less than 300 ng/dL (to convert to nanomoles per liter, multiply by 0.0347) and free testosterone level less than 5 ng/dL, and the presence of at least 1 specific symptom (low libido, erectile dysfunction, or osteoporosis) or 2 or more less-specific symptoms (sleep disturbance, depressed mood, lethargy, or diminished physical performance) and not using prescription testosterone. Any man who was using testosterone was considered to have treated AD.

Results  Data were available for 1486 Boston Area Community Health Survey participants (mean age, 46.4 years; age range, 30-79 years). A total of 5.5% (95% confidence interval, 3.5-8.5) men met the criteria for having untreated, symptomatic AD, and 0.8% (95% confidence interval, 0.4-1.4) met the criteria for having treated AD. Considering all cases, the proportion treated was 12.2%. Men with untreated AD seemed to have adequate access to care.

Conclusions  Under our assumptions, a large majority (87.8%) of 97 men in our groups with AD were not receiving treatment despite adequate access to care. The reasons for this are unknown but could be due to unrecognized AD or unwillingness to prescribe testosterone therapy.

Author Affiliations: New England Research Institutes, Watertown, Massachusetts (Drs Hall, Araujo, Travison, and McKinlay and Ms Esche); and GlaxoSmithKline PLC, Research Triangle Park, North Carolina (Drs Williams and Clark).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Men, Androgen Deficiency, and Pharmaceutical Promotion
Thomas E. Finucane
Arch Intern Med. 2009;169(1):88.
EXTRACT | FULL TEXT  

Men, Androgen Deficiency, and Pharmaceutical Promotion—Reply
Susan A. Hall, Andre B. Araujo, Thomas G. Travison, Gretchen R. Esche, John B. McKinlay, Richard V. Clark, and Rachel E. Williams
Arch Intern Med. 2009;169(1):88-89.
EXTRACT | FULL TEXT  

RELATED ARTICLE

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(10):1026.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Men, Androgen Deficiency, and Pharmaceutical Promotion
Finucane
Arch Intern Med 2009;169:88-88.
FULL TEXT  

Men, Androgen Deficiency, and Pharmaceutical Promotion--Reply
Hall et al.
Arch Intern Med 2009;169:88-89.
FULL TEXT